New instrument could aid diagnosis by helping surgeons pinpoint the best place for a biopsy. Researchers have developed an optical biopsy system that can distinguish between cancerous and… read more.
Blood glucose control is key to lowering the risk of cancer in obese persons with type 2 diabetes, researchers reported on Dec. 6, 20231 in Diabetes Care. “What… read more.
Research by the Oregon State University College of Pharmacy suggests that a vaccine stimulating production of a protein critical to the skin’s antioxidant network could help people bolster… read more.
Common immune microenvironments across different types of cancer. Using data from over 300 patient tumors, researchers have described 12 classes of ‘immune archetypes’ to classify cancer tumors. Their… read more.
Stem cells have promised to be the catalyst for major strides in medical research for decades. While progress in some fields has been slower than initially hoped, scientists… read more.
Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient’s own immune cells to fight cancer. These treatments have energized cancer care, especially for people… read more.
Recent trends also highlight global disparities in cancer burden. Cancer deaths rose to 10 million and new cases jumped to over 23 million globally in 2019, according to… read more.
Radiation monotherapy is an effective noninvasive treatment for oligometastatic renal cell carcinoma (RCC), researchers reported on Oct. 28, 2021 in The Lancet Oncology. “These findings are exciting because… read more.
Researchers at Vanderbilt University Medical Center have discovered a nanoparticle released from cells, called a “supermere,” which contains enzymes, proteins and RNA associated with multiple cancers, cardiovascular disease,… read more.
It’s worth noting, in light of recently published research, that a majority of people won’t be diagnosed with cancer in their lifetimes. According to the National Cancer Institute,… read more.
Kite announced the FDA has granted approval for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute… read more.
– Bristol Myers Squibb announced three-year data from the CheckMate -743 trial that demonstrated a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
